These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18556642)

  • 1. Modeling the incubation period of inhalational anthrax.
    Wilkening DA
    Med Decis Making; 2008; 28(4):593-605. PubMed ID: 18556642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the incubation period of anthrax.
    Brookmeyer R; Johnson E; Barry S
    Stat Med; 2005 Feb; 24(4):531-42. PubMed ID: 15678407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative pathology of inhalational anthrax I: quantitative microscopic findings.
    Grinberg LM; Abramova FA; Yampolskaya OV; Walker DH; Smith JH
    Mod Pathol; 2001 May; 14(5):482-95. PubMed ID: 11353060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, D.C., in 2001.
    Baggett HC; Rhodes JC; Fridkin SK; Quinn CP; Hageman JC; Friedman CR; Dykewicz CA; Semenova VA; Romero-Steiner S; Elie CM; Jernigan JA
    Clin Infect Dis; 2005 Oct; 41(7):991-7. PubMed ID: 16142664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak.
    Brookmeyer R; Blades N; Hugh-Jones M; Henderson DA
    Biostatistics; 2001 Jun; 2(2):233-47. PubMed ID: 12933552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling low-dose mortality and disease incubation period of inhalational anthrax in the rabbit.
    Gutting BW; Marchette D; Sherwood R; Andrews GA; Director-Myska A; Channel SR; Wolfe D; Berger AE; Mackie RS; Watson BJ; Rukhin A
    J Theor Biol; 2013 Jul; 329():20-31. PubMed ID: 23567649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus anthracis contamination and inhalational anthrax in a mail processing and distribution center.
    Sanderson WT; Stoddard RR; Echt AS; Piacitelli CA; Kim D; Horan J; Davies MM; McCleery RE; Muller P; Schnorr TM; Ward EM; Hales TR
    J Appl Microbiol; 2004; 96(5):1048-56. PubMed ID: 15078521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhalational anthrax due to bioterrorism: would current Centers for Disease Control and Prevention guidelines have identified the 11 patients with inhalational anthrax from October through November 2001?
    Mayer TA; Morrison A; Bersoff-Matcha S; Druckenbrod G; Murphy C; Howell J; Hanfling D; Cates R; Pauze D; Earls J
    Clin Infect Dis; 2003 May; 36(10):1275-83. PubMed ID: 12746773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anthrax--an overview at 2002].
    Mozes YN; Winder A; Tadmor B; Rotman E; Sagi R; Hourvitz A
    Harefuah; 2002 May; 141 Spec No():63-72, 121, 120. PubMed ID: 12170557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative models of the dose-response and time course of inhalational anthrax in humans.
    Toth DJ; Gundlapalli AV; Schell WA; Bulmahn K; Walton TE; Woods CW; Coghill C; Gallegos F; Samore MH; Adler FR
    PLoS Pathog; 2013 Aug; 9(8):e1003555. PubMed ID: 24058320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of toxins to the pathogenesis of inhalational anthrax.
    Tournier JN; Quesnel-Hellmann A; Cleret A; Vidal DR
    Cell Microbiol; 2007 Mar; 9(3):555-65. PubMed ID: 17223930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation model for syndromic surveillance: assessing the performance of a temporal algorithm.
    Buckeridge DL; Switzer P; Owens D; Siegrist D; Pavlin J; Musen M
    MMWR Suppl; 2005 Aug; 54():109-15. PubMed ID: 16177701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sverdlovsk revisited: modeling human inhalation anthrax.
    Wilkening DA
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7589-94. PubMed ID: 16679412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics.
    Vietri NJ; Purcell BK; Tobery SA; Rasmussen SL; Leffel EK; Twenhafel NA; Ivins BE; Kellogg MD; Webster WM; Wright ME; Friedlander AM
    J Infect Dis; 2009 Feb; 199(3):336-41. PubMed ID: 19099484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating detection of an inhalational anthrax outbreak.
    Buckeridge DL; Owens DK; Switzer P; Frank J; Musen MA
    Emerg Infect Dis; 2006 Dec; 12(12):1942-9. PubMed ID: 17326949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of anthrax.
    Bartlett JG; Inglesby TV; Borio L
    Clin Infect Dis; 2002 Oct; 35(7):851-8. PubMed ID: 12228822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of inhalational anthrax in the U.S. outbreak.
    Brookmeyer R; Blades N
    Science; 2002 Mar; 295(5561):1861. PubMed ID: 11884746
    [No Abstract]   [Full Text] [Related]  

  • 18. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak.
    Brookmeyer R; Johnson E; Bollinger R
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):10129-32. PubMed ID: 12890865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal models of human anthrax: the Quest for the Holy Grail.
    Goossens PL
    Mol Aspects Med; 2009 Dec; 30(6):467-80. PubMed ID: 19665473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhalational anthrax.
    Cuneo BM
    Respir Care Clin N Am; 2004 Mar; 10(1):75-82. PubMed ID: 15062228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.